You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IDH mutant glioma

Showing 1 - 25 of 1,662
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Adult Gliomas, Mixed Trial in San Francisco (Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG), Magnetic Resonance Image

Recruiting
  • Adult Gliomas, Mixed
  • Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)
  • Magnetic Resonance Image (MRI)
  • San Francisco, California
    University of California, San Francisco
May 9, 2023

Glioma, IDH Mutation, Astrocytoma Trial in Philadelphia (Retifanlimab, All-trans retinoic acid)

Not yet recruiting
  • Glioma
  • +3 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Jul 22, 2022

Glioma, Gliomas, High Grade Glioma Trial run by the National Cancer Institute (NCI) (3T MRI scanner)

Recruiting
  • Glioma
  • +4 more
  • 3T MRI scanner
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Astrocytoma, Oligodendroglioma, Adult, Glioma, Malignant Trial in Saint Louis (temporally-modulated pulsed radiotherapy (TMPRT))

Recruiting
  • Astrocytoma
  • +2 more
  • temporally-modulated pulsed radiotherapy (TMPRT)
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 19, 2023

Low Grade Glioma of Brain Trial in Durham (PEPIDH1M vaccine + vorasidenib)

Not yet recruiting
  • Low Grade Glioma of Brain
  • PEPIDH1M vaccine + vorasidenib
  • Durham, North Carolina
    Duke University Medical Center
Nov 2, 2022

IDH-mutant and IDH-wildtype Glioma Patients After

Recruiting
  • Glioma
  • RS-fMRI
  • Saint Louis, Missouri
    Washington University School of Medicine
Mar 8, 2022

Glioma Trial (AB-218)

Not yet recruiting
  • Glioma
  • (no location specified)
Mar 29, 2022

Glioblastoma Multiforme, Adult, Glioblastoma, IDH-mutant Trial (Dose escalation + Reduced Margin Adaptive Radiotherapy)

Not yet recruiting
  • Glioblastoma Multiforme, Adult
  • Glioblastoma, IDH-mutant
  • Dose escalation + Reduced Margin Adaptive Radiotherapy
  • (no location specified)
Oct 3, 2022

Epilepsy; Seizure Trial (ES-481)

Withdrawn
  • Epilepsy; Seizure
  • (no location specified)
Mar 28, 2022

Advanced Solid Tumor, IDH1 Mutation, Glioma Trial in Pittsburgh (ivosidenib and nivolumab)

Recruiting
  • Advanced Solid Tumor
  • +2 more
  • ivosidenib and nivolumab
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 14, 2022

Vascular Habitats Within Astrocytoma Grade 4 at Molecular,

Recruiting
  • Astrocytoma, Grade IV
  • +7 more
    • Valencia, Spain
      Biomedical Data Science Lab. Universitat Politècnica de València
    May 11, 2022

    Gliomas Trial in Miami, Boston, New York (Nivolumab)

    Active, not recruiting
    • Gliomas
    • Miami, Florida
    • +3 more
    May 5, 2022

    Glioma, IDH Mutation Trial (BAY 2402234)

    Withdrawn
    • Glioma
    • IDH Mutation
    • BAY 2402234
    • (no location specified)
    Dec 17, 2021

    Supramaximal Resection Versus Maximal Resection for High-Grade

    Recruiting
    • Glioblastoma
    • +11 more
    • Supramaximal resection
    • Maximal safe resection
    • San Francisco, California
    • +7 more
    Nov 1, 2023

    Glioblastoma, Glioblastoma Multiforme, Glioma Trial in Phoenix, San Francisco (Niraparib, Radiation therapy)

    Recruiting
    • Glioblastoma
    • +5 more
    • Phoenix, Arizona
    • +1 more
    Dec 7, 2021

    Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma Trial in Boston (Niraparib, Resection/Treatment with Niraparib)

    Recruiting
    • Low-grade Glioma
    • +4 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Oct 19, 2022

    Recurrent IDH1/2 Mutated Glioma Trial in Paris (Azacitidine)

    Recruiting
    • Recurrent IDH1/2 Mutated Glioma
    • Paris, France
      Pitie Salpetriere Hospital
    Aug 29, 2022

    Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,

    Not yet recruiting
    • Diffuse Astrocytoma, IDH-Mutant
    • +20 more
    • NEO212 Oral Capsule
    • +8 more
    • (no location specified)
    Sep 18, 2023

    Glioma, Malignant, Computer-Assisted Trial in Shanghai (Validation of IDH1 mutations from the radiomics model)

    Active, not recruiting
    • Glioma, Malignant
    • Computer-Assisted
    • Validation of IDH1 mutations from the radiomics model
    • Shanghai, Shanghai, China
      Huashan Hospital, Fudan University
    Jul 23, 2023

    Brain Tumor, Cancer Trial run by the National Cancer Institute (NCI) (Zotiraciclib)

    Not yet recruiting
    • Brain Tumor
    • Cancer
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

    Not yet recruiting
    • Recurrent Glioblastoma, IDH-Wildtype
    • +2 more
    • Biospecimen Collection
    • +2 more
    • (no location specified)
    May 13, 2023

    Single Photon Emission Computed Tomography/Computed Tomography

    Not yet recruiting
    • Brain Glioma
    • SPECT with pentavalent 99mTc DMSA
    • (no location specified)
    Oct 23, 2022

    Advanced Malignant Solid Tumor, Glioblastoma, Recurrent Cholangiocarcinoma Trial in United States (Olaparib)

    Recruiting
    • Advanced Malignant Solid Neoplasm
    • +6 more
    • Costa Mesa, California
    • +49 more
    Aug 24, 2022

    Correlation Between SPECT/CT and IDH Mutation in Brain Glioma

    Not yet recruiting
    • Brain Glioma
      • (no location specified)
      Oct 23, 2022

      Astrocytoma Trial (Vorasidenib, Pembrolizumab)

      Not yet recruiting
      • Astrocytoma
      • (no location specified)
      Aug 1, 2022